Phase 2b/3 Trial of NuSepin® in COVID-19 Pneumonia Patients
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
A Randomized, Double-blinded, Placebo-controlled, Parallel-treatment Group, Adaptive Design,
Multi-center, Phase 2b/3 Trial to Evaluate Efficacy and Safety of NuSepin® Intravenous
Infusion in COVID-19 Pneumonia Patients